Biologics Contract Development Market: Addressing the Rising Demand for Advanced Healthcare Solutions

According to Next Move Strategy Consulting, the global Biologics Contract Development Market is predicted to reach USD 14 billion by 2030 with a CAGR of 9% from 2024-2030. As the global burden of these conditions increases, so does the demand for advanced, targeted therapies that biologics offer. Biologics, which are derived from living organisms, provide highly specific treatments for complex diseases, making them a vital component of modern healthcare.

Download Free Sample: https://www.nextmsc.com/biologics-contract-development-market/request-sample 

According to the American Cancer Society, approximately 20 million new cancer cases were diagnosed in 2022, with projections indicating that the number could reach 35 million by 2050. As the incidence of chronic diseases grows, pharmaceutical and biotechnology companies are increasingly turning to contract development organizations (CDOs) to assist with the development and manufacturing of biologic therapies. This growing reliance on CDOs to bring novel biologics to market is fueling the expansion of the biologics contract development market.

Factors Driving Market Growth

One of the key drivers of the biologics contract development market is the rising interest in exosome-based therapeutics. Exosomes, tiny vesicles secreted by cells, have garnered significant attention in the biopharmaceutical industry due to their potential applications in regenerative medicine, drug delivery, and cancer therapy. Exosome-based therapies require specialized knowledge and infrastructure, which has led pharmaceutical and biotech companies to partner with CDOs that offer expertise in exosome production. For example, in February 2024, EXO Biologics SA launched Expert, a contract development and manufacturing organization (CDMO) focused on addressing the lack of exosome production capabilities in the industry.

Additionally, the aging global population is increasing the demand for biologic therapies. According to the World Health Organization, the proportion of people aged 60 years and above is expected to rise to 1.4 billion by 2030 and is projected to double by 2050. As the elderly demographic grows, so does the prevalence of age-related diseases such as arthritis, which are increasingly treated with biologics. The rise in demand for biologics is thus contributing to the market's expansion, as healthcare providers seek innovative solutions to meet the complex needs of aging populations.

Despite these positive drivers, the biologics contract development market faces significant challenges. The high costs associated with biologic drug development, particularly compared to conventional small-molecule drugs, present a substantial barrier. Biologic drug development is a complex and expensive process, involving costly manufacturing procedures, extended pre-clinical trials, and large-scale clinical trials. These financial challenges can limit the ability of some companies to invest in biologic therapies, impacting the overall growth of the market.

Market Segmentation

The biologics contract development market is categorized by product type, service type, end-user, and geography.

Inquire Before Buying: https://www.nextmsc.com/biologics-contract-development-market/inquire-before-buying 

• Product Type:
  
  
• Antibodies: These are among the most widely used biologic therapies, including monoclonal antibodies for the treatment of cancer, autoimmune diseases, and infectious diseases.
• Cell Therapies: Involve the use of living cells to treat diseases, including cancer immunotherapies and regenerative medicine.
• Vaccines: Biologic vaccines are increasingly developed using modern technologies to prevent and treat infectious diseases.
• Other: This category includes a variety of other biologics such as gene therapies and enzyme replacement therapies.

• Service Type:
  
  
• Mammalian: This service type includes the use of mammalian cell cultures to produce biologic drugs, a widely used method for antibody production.
• Microbial: Involves the use of microorganisms such as bacteria or yeast in the production of biologics, offering an alternative to mammalian cell culture.
• Other: Includes additional methods such as plant-based expression systems for biologics production.

• End-User:
  
  
• Clinical: CDOs provide contract development services to clinical researchers for biologics testing and early-phase development.
• Hospital: Hospitals require biologics for patient treatments, leading to partnerships with CDOs for biologics development.
• Pharmaceutical: Pharmaceutical companies are key end-users, relying on CDOs for comprehensive biologics development and manufacturing solutions.
• Biotechnology: Biotech companies leverage CDOs for specialized biologics development services, often focusing on innovative therapies.
• Other: Includes academic institutions and government agencies involved in biologics research and development.

• Geography:
  
  
• North America: Dominates the biologics contract development market due to the high incidence of chronic conditions such as spinal disorders, which require advanced biologic treatments. The U.S. is particularly notable, with approximately 17,000 new spinal cord injury cases reported annually. The region also benefits from an extensive network of CDOs that provide advanced technologies and expertise to pharmaceutical companies.
• Asia-Pacific: The market in Asia-Pacific is expected to grow steadily, driven by the increasing demand for innovative biologic therapies, including cancer immunotherapies. Countries such as India are experiencing rapid growth in their pharmaceutical sectors, with India’s pharmaceutical industry expected to reach USD 130 billion by 2030. CDMOs in the region are helping companies meet the rising demand for specialized biologics.
• Europe: This region is also a significant player in the biologics contract development market, driven by its robust healthcare infrastructure and increasing demand for biologics to address diseases such as cancer and autoimmune disorders.

Market Leaders and Strategic Developments

Key players in the biologics contract development market include AGC Biologics, Boehringer Ingelheim, Catalent, Cell Therapies, WuXi Biologics, FUJIFILM Diosynth Biotechnologies, Lonza, Samsung Biologics, and others. These companies are employing various strategies such as innovation, business expansions, and collaborations to maintain their leadership in the market.

For instance, AGC Biologics introduced the AGCellerate program in June 2023, providing biopharmaceutical developers with IND-ready GMP materials for biologic drug development. In another move, Cell and Gene Therapy Catapult partnered with Albumedix to explore albumin-based solutions for advanced therapies, which could support the growth of cell and gene therapies, a rapidly growing sector in the biologics market.

In December 2023, WuXi Biologics opened a Biosafety Testing Center in Shanghai to enhance its testing capabilities for biological and vaccine drug products, supporting early-phase development. This facility further solidifies the company's role in supporting biologics development across the globe.

Conclusion

The biologics contract development market is growing rapidly due to the rising prevalence of chronic diseases, the increasing demand for biologic therapies, and the growing adoption of exosome-based therapeutics. Despite challenges such as high development costs, the market is set for continued expansion, driven by technological advancements and increasing demand for personalized medicine. Leading players in the industry are focusing on innovation and strategic partnerships to maintain their dominance and address the growing need for advanced biologic therapies.

For more information, please contact:

Next Move Strategy Consulting

E-Mail: info@nextmsc.com

Direct: +1-217-650-7991

Website: www.nextmsc.com

Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube

About Next Move Strategy Consulting: 

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.